Literature DB >> 21555676

Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.

Esa M Davis1, Lawrence J Appel, Xuelei Wang, Tom Greene, Brad C Astor, Mahboob Rahman, Robert Toto, Michael S Lipkowitz, Velvie A Pogue, Jackson T Wright.   

Abstract

Blood pressure (BP) guidelines that set target BP levels often rely on analyses of achieved BP from hypertension treatment trials. The objective of this article was to compare the results of analyses of achieved BP to intention-to-treat analyses on renal disease progression. Participants (n=1094) in the African-American Study of Kidney Disease and Hypertension Trial were randomly assigned to either usual BP goal defined by a mean arterial pressure goal of 102 to 107 mm Hg or lower BP goal defined by a mean arterial pressure goal of ≤92 mm Hg. Median follow-up was 3.7 years. Primary outcomes were rate of decline in measured glomerular filtration rate and a composite of a decrease in glomerular filtration rate by >50% or >25 mL/min per 1.73 m(2), requirement for dialysis, transplantation, or death. Intention-to-treat analyses showed no evidence of a BP effect on either the rate of decline in glomerular filtration rate or the clinical composite outcome. In contrast, the achieved BP analyses showed that each 10-mm Hg increment in mean follow-up achieved mean arterial pressure was associated with a 0.35 mL/min per 1.73 m(2) (95% CI: 0.08 to 0.62 mL/min per 1.73 m(2); P=0.01) faster mean glomerular filtration rate decline and a 17% (95% CI: 5% to 32%; P=0.006) increased risk of the clinical composite outcome. Analyses based on achieved BP lead to markedly different inferences than traditional intention-to-treat analyses, attributed in part to confounding of achieved BP with comorbidities, disease severity, and adherence. Clinicians and policy makers should exercise caution when making treatment recommendations based on analyses relating outcomes to achieved BP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21555676      PMCID: PMC3150108          DOI: 10.1161/HYPERTENSIONAHA.111.169367

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  31 in total

1.  K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

Authors:  B Neal; S MacMahon; N Chapman
Journal:  Lancet       Date:  2000-12-09       Impact factor: 79.321

Review 4.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

Authors:  George L Bakris; Matthew R Weir; Shahnaz Shanifar; Zhongxin Zhang; Janice Douglas; David J van Dijk; Barry M Brenner
Journal:  Arch Intern Med       Date:  2003-07-14

7.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

8.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

Authors:  Jennifer J Gassman; Tom Greene; Jackson T Wright; Lawrence Agodoa; George Bakris; Gerald J Beck; Janice Douglas; Ken Jamerson; Julia Lewis; Michael Kutner; Otelio S Randall; Shin-Ru Wang
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

View more
  21 in total

Review 1.  Recognition and Management of Hypertension in Older Persons: Focus on African Americans.

Authors:  Carolyn H Still; Keith C Ferdinand; Gbenga Ogedegbe; Jackson T Wright
Journal:  J Am Geriatr Soc       Date:  2015-10       Impact factor: 5.562

2.  Rate of change in renal function and mortality in elderly treated hypertensive patients.

Authors:  Enayet K Chowdhury; Robyn G Langham; Zanfina Ademi; Alice Owen; Henry Krum; Lindon M H Wing; Mark R Nelson; Christopher M Reid
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-21       Impact factor: 8.237

Review 3.  Current and Future Treatment of Hypertension in the SPRINT Era.

Authors:  Robert A Phillips
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Oct-Dec

Review 4.  Dangers of Overly Aggressive Blood Pressure Control.

Authors:  Faisal Rahman; John W McEvoy
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

5.  Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study.

Authors:  Amanda H Anderson; Wei Yang; Raymond R Townsend; Qiang Pan; Glenn M Chertow; John W Kusek; Jeanne Charleston; Jiang He; RadhaKrishna Kallem; James P Lash; Edgar R Miller; Mahboob Rahman; Susan Steigerwalt; Matthew Weir; Jackson T Wright; Harold I Feldman
Journal:  Ann Intern Med       Date:  2015-02-17       Impact factor: 25.391

Review 6.  Pros and Cons of Intensive Systolic Blood Pressure Lowering.

Authors:  Holly Kramer; Richard Cooper
Journal:  Curr Hypertens Rep       Date:  2018-03-06       Impact factor: 5.369

Review 7.  What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease?

Authors:  Gopesh K Modi; Rajiv Agarwal
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

Review 8.  Beta-blockers for hypertension.

Authors:  Charles S Wiysonge; Hazel A Bradley; Jimmy Volmink; Bongani M Mayosi; Lionel H Opie
Journal:  Cochrane Database Syst Rev       Date:  2017-01-20

Review 9.  Hypertension and chronic kidney disease progression: why the suboptimal outcomes?

Authors:  Anil K Bidani; Karen A Griffin; Murray Epstein
Journal:  Am J Med       Date:  2012-08-17       Impact factor: 4.965

Review 10.  Blood pressure targets in the treatment of high blood pressure: a reappraisal of the J-shaped phenomenon.

Authors:  F D Fuchs; S C Fuchs
Journal:  J Hum Hypertens       Date:  2013-08-22       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.